ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

ClinicalTrials.gov ID: NCT02945800

Public ClinicalTrials.gov record NCT02945800. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults

Study identification

NCT ID
NCT02945800
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Enrollment
59 participants

Conditions and interventions

Interventions

  • Gemcitabine Drug
  • nab-Paclitaxel Drug

Drug

Eligibility (public fields only)

Age range
3 Years to 30 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 24, 2016
Primary completion
Nov 18, 2024
Completion
Feb 16, 2025
Last update posted
Apr 1, 2026

2016 – 2025

United States locations

U.S. sites
14
U.S. states
10
U.S. cities
14
Facility City State ZIP Site status
University of Alabama at Birmingham Comprehensive Cancer Center Birmingham Alabama 35294
Children's Hospital Los Angeles Los Angeles California 90027
Connecticut Children's Medical Center Hartford Connecticut 06103
A.I. duPont Hospital for Children, Delaware - Nemours Wilmington Delaware 19603
Shand's Hospital for Children at the University of Florida Gainesville Florida 32608
Nemours Children's Clinic Jacksonville Florida 32207
Holtz Children's Hospital at the University of Miami Miami Florida 33136
H. Lee Moffitt Cancer Center and Research Institute, Coordinating Center Tampa Florida 33612
University of Kentucky Lexington Kentucky 40506
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599
Carolinas Medical Center, Levine Cancer Institute Charlotte North Carolina 28303
Nationwide Children's Hospital Columbus Ohio 43205
Vanderbilt - Ingram Cancer Center Nashville Tennessee 37232

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02945800, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 1, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02945800 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →